Dermatofibrosarcoma protuberans – the use of neoadjuvant imatinib for treatment of an uncommon breast malignancy: a case report
Open Access
- 19 December 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Medical Case Reports
- Vol. 13 (1), 1-6
- https://doi.org/10.1186/s13256-019-2316-0
Abstract
Dermatofibrosarcoma protuberans is a rare soft tissue malignancy that, if left untreated, can be locally destructive and life-threatening. Dermatofibrosarcoma protuberans is uncommon in the breast, and the similarity of its morphologic features with other spindle cell malignancies can make correct identification difficult. Immunohistochemistry and molecular testing can aid in the correct diagnosis when there is diagnostic uncertainty. Imatinib, a selective tyrosine kinase inhibitor, has been used for adjuvant treatment of dermatofibrosarcoma protuberans following surgical resection. When used as a neoadjuvant treatment, imatinib offers the opportunity to decrease tumor size prior to surgery to lessen the chance for disfigurement. We present the case of a Caucasian woman who was 46-year-old when she first noted a mass in her right breast in 2015; she was initially diagnosed as having metaplastic breast carcinoma. Mastectomy and systemic chemotherapy were planned; however, after review of pathology at a referral center, the diagnosis was changed to dermatofibrosarcoma protuberans. She was treated with 4 months of neoadjuvant imatinib with adequate tumor shrinkage to perform breast conservation. This patient’s case stresses the importance of correctly diagnosing this rare breast tumor through the histopathologic appearance of dermatofibrosarcoma protuberans, molecular pathogenesis, and immunohistochemistry. These techniques can help differentiate dermatofibrosarcoma protuberans from metaplastic breast carcinoma and other spindle cell lesions of the breast. This is critical, as the treatment options for metaplastic breast carcinoma significantly differ from treatment options for dermatofibrosarcoma protuberans. This case describes the use of imatinib as a neoadjuvant option to reduce preoperative tumor size and improve surgical outcomes.Keywords
This publication has 29 references indexed in Scilit:
- Treatment Options for Metaplastic Breast CancerISRN Oncology, 2012
- Review of Metaplastic Carcinoma of the Breast: Imaging Findings and Pathologic FeaturesJournal of Clinical Imaging Science, 2012
- Imatinib Mesylate as a Preoperative Therapy in Dermatofibrosarcoma: Results of a Multicenter Phase II Study on 25 PatientsClinical Cancer Research, 2010
- Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans—a case reportOral and Maxillofacial Surgery, 2008
- Dermatofibrosarcoma Protuberans: Recent Clinical ProgressAnnals of Surgical Oncology, 2007
- Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34British Journal of Dermatology, 2007
- Spindle cell lesions of the breast—the pathologic differential diagnosisBreast Cancer Research and Treatment, 2007
- Treatment of Recurrent Dermatofibrosarcoma Protuberans with Imatinib Mesylate, Followed by Mohs Micrographic SurgeryDermatologic Surgery, 2007
- Imatinib Mesylate in the Treatment of a Large Unresectable Dermatofibrosarcoma Protuberans: A Case StudyDermatologic Surgery, 2006
- Dermatofibrosarcoma Protuberans: A Partial Response to Imatinib TherapyDermatologic Surgery, 2006